Advanced or Metastatic HER2-Negative Gastroesophageal Adenocarcinomas Market Outlook

Thelansis’s “Advanced or Metastatic HER2-Negative Gastroesophageal Adenocarcinomas Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic HER2-Negative Gastroesophageal Adenocarcinomas treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Advanced or Metastatic HER2-Negative Gastroesophageal Adenocarcinomas Overview

Advanced or metastatic HER2-negative gastroesophageal adenocarcinoma encompasses gastric, gastroesophageal junction, and oesophageal adenocarcinomas lacking HER2 amplification, representing the majority of advanced disease and characterised by considerable molecular heterogeneity driving variable treatment responsiveness. Comprehensive molecular profiling at diagnosis encompasses PD-L1 combined positive score, microsatellite instability status, and CLDN18.2 expression, each carrying distinct therapeutic implications across this biomarker-stratified disease. Patients present with epigastric pain, dysphagia, early satiety, weight loss, and anaemia, with many diagnosed at advanced stages given insidious symptom onset. Nivolumab or pembrolizumab combined with platinum-fluoropyrimidine chemotherapy constitutes the established frontline standard for PD-L1 CPS-positive disease, delivering meaningful survival benefit over chemotherapy alone, with benefit magnitude correlating with CPS expression level. MSI-H tumours, though a minority, derive substantial benefit from immunotherapy-based approaches. Zolbetuximab, a CLDN18.2-targeted monoclonal antibody, combined with chemotherapy represents a significant approved frontline advance specifically for CLDN18.2-positive, HER2-negative disease, expanding biomarker-directed therapeutic options. Trifluridine-tipiracil and ramucirumab-paclitaxel address chemorefractory later-line disease. FGFR2b overexpression represents an emerging actionable target under active clinical investigation. Prognosis remains poor in advanced disease despite biomarker-driven advances; multidisciplinary tumour board evaluation, nutritional support, and early palliative integration are indispensable to patient-centred care.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)